reduction of new virions infectivity [15,16].
The first randomized, double-blind, placebo-controlled clinical trial about the anti-HIV-1 activity of HCQ was published in 1995. In this study, 40 asymptomatic HIV-infected patients received either 800 mg/day HCQ or placebo for eig